Physician profile
Salim A Jaffer
NPI 1043387566
$25,390.24
in general payments reported to CMS, 2019-2025
30 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $299 · 2021: $21K · 2022: $1,118 · 2023: $688 · 2024: $722 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.18 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $20,855.16 | 2021 | |
| Abbvie INC. | $1,732.70 | 2019-2025 | |
| Janssen Biotech, INC. | $454.57 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $425.70 | 2019-2024 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $264.24 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $261.25 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.15 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $182.17 | 2019-2025 | |
| Braintree Laboratories, INC. | $141.81 | 2019-2020 | |
| Genzyme Corporation | $98.79 | 2022-2024 | |
| Ucb, INC. | $94.49 | 2019 | |
| Ardelyx, INC. | $90.18 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $83.38 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $63.50 | 2019-2025 | Rebyota |
| Pfizer INC. | $59.09 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $53.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.04 | 2024 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $35.67 | 2019 | |
| Madrigal Pharmaceuticals | $27.14 | 2025 | Rezdiffra |
| Shionogi INC | $22.66 | 2019 | |
| Celgene Corporation | $21.88 | 2021 | |
| Aimmune Therapeutics, INC. | $18.83 | 2024 | |
| Lilly USA, LLC | $18.64 | 2024 | Omvoh |
| Ethicon US, LLC | $18.35 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.87 | 2022 | |
| Merck Sharp & Dohme LLC | $14.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.72 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $4.87 | 2024 | Blueboost |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Jaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.